The European Medicines Agency (EMA) has accepted for review Mylan’s (Nasdaq: MYL) regulatory submission its version of diabetes treatment insulin glargine, referencing Lantus, the original blockbuster product from France’s Sanofi (Euronext: SAN).
The Netherlands-incorporated drugmaker has co-developed the treatment with India's leading biotech firm, Biocon (NSE: BIOCON).
"There is a significant unmet need around the world for more affordable versions of injectable insulin products."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze